Ajinomoto Co., Ltd.

Ea Pharma Co., Ltd.

Ajinomoto., Inc.

Masaru Takayanagi

Wataru Miyanaga

Takao Ikenoue

Yumiko Fukuda

Satoru Okamoto

Hideyuki Tanaka

Naoyuki Fukuchi

Naoyuki Yamada

Ryusuke Hirama

Sen Takeshita

Shunji Takehana

Naoko Arashida

Toshihiro Hatanaka

Tadakiyo Nakagawa

Seiji Niwa

Kazuyuki Sagi

Nobuo Kondo

Takashi Kayahara

Yoko Masuzawa

Akiyo Yamazaki

Mitsuo Takahashi

Shingo Makino

Yoko Kageyama

Masataka Shoji

Itsuya Tanabe

Kayo Otani

Yuki Saitou

Tatsuya Ishikawa

Yoriko Okamatsu

Masahiro Yamanashi

A method of screening a compound having a hypoglycemic effect (hereinafter referred to as 'hypoglycemic compound'), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the &#x3b2; subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the &#x3b2; subunit of a trimeric GTP-binding protein, as the active ingredient, etc.

Remedy for diabetes

The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. wherein R represents an alkoxy group, R' represents an oxazolylpropionyl group or a thiazolylpropionyl group, and R&#x2033; represent a hydrogen atom.

Fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof

Compounds represented by formula (1) and pharmaceutically acceptable salt thereofs: wherein each symbol is as defined in the specification, are useful as inhibitors of an activated blood coagulation factor X. Compositions which contain, as an active ingredient, an FXa selective low-molecular weight FXa inhibitor having a short serum half-life are particularly useful as anticoagulants for an extracorporeal blood circuit.

Benzamidine compound

The present invention provides a lactam compound, a sugar transport enhancement agent containing this compound as an active ingredient, an agent for the prevention and/or treatment of diabetes mellitus, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macrovascular disease, glucose tolerance anomaly, obesity and the like. In addition, the present invention also provides a preparation method for the novel lactam compound, and a preparation intermediate thereof.

Lactam compound, a method for producing the same, and a diabetic therapy by administering the same

Benzamidine derivatives of the following formulae or analogs thereof, i.e., pharmaceutically acceptable salts thereof, are provided. These compounds or salts thereof have a blood-coagulation inhibiting effect based on an excellent effect of inhibiting the action of activated blood coagulation factor X, and they are useful as anticoagulants 

Benzamidine derivatives

Aminoisoquinoline derivatives of the following formulae or analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an excellent effect of inhibiting activated blood-coagulation factor X, and they are useful as anticoagulants or agents for preventing or treating thrombi or emboli.

Aminoisoquinoline derivatives

Growing community of inventors

Kawasaki, Japan

Masaru Takayanagi